Sitravatinib in Metastatic Breast Cancer

Summary

This study evaluates the efficacy of sitravatinib in patients with metastatic breast cancer. All study participants will receive sitravatinib, 100 mg daily, until their cancer worsens, or until they develop intolerable side effects.

Timeline

Start

2021-09-22

Primary completion

2023-01-22

Completion

2023-01-22

Drugs

Indications